Smartleaf Asset Management LLC Sells 14,660 Shares of Global X Genomics & Biotechnology ETF $GNOM

Smartleaf Asset Management LLC cut its holdings in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 75.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,888 shares of the company’s stock after selling 14,660 shares during the quarter. Smartleaf Asset Management LLC owned about 0.40% of Global X Genomics & Biotechnology ETF worth $187,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in GNOM. Atria Investments Inc increased its holdings in shares of Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after purchasing an additional 2,073 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 86.7% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock worth $188,000 after buying an additional 10,358 shares during the period. Sei Investments Co. grew its stake in Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares during the last quarter. Insight Advisors LLC PA raised its holdings in Global X Genomics & Biotechnology ETF by 47.9% in the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock valued at $503,000 after acquiring an additional 19,319 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its position in Global X Genomics & Biotechnology ETF by 8.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after acquiring an additional 6,708 shares during the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Up 0.6%

Global X Genomics & Biotechnology ETF stock opened at $45.70 on Friday. Global X Genomics & Biotechnology ETF has a 12 month low of $27.20 and a 12 month high of $51.42. The stock’s 50 day moving average is $47.26 and its 200-day moving average is $42.62. The company has a market capitalization of $49.81 million, a price-to-earnings ratio of -19.53 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Dividend Announcement

The company also recently disclosed a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were issued a $0.5912 dividend. This represents a yield of 259.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio is currently -26.50%.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.